News · 26 weeks69-14%
2026-04-192026-10-11
Mix4090d
- SEC Filings19(48%)
- Other17(43%)
- Earnings2(5%)
- Insider1(3%)
- Leadership1(3%)
Latest news
25 items- SECSEC Form 8-K filed by Co-Diagnostics Inc.8-K - Co-Diagnostics, Inc. (0001692415) (Filer)
- PRCo-Diagnostics Highlights PCR Platform Capabilities for Potential Plague DetectionExisting Sputum Sample-Preparation Technology Provides Potential Foundation for Plague DiagnosticsDraws on Rapid-Response Experience with COVID-19, Mpox and Ebola Supported by Expanded Manufacturing InfrastructureSALT LAKE CITY, Oct. 15, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today highlighted capabilities of its Co-Dx PCR Pro®* point-of-care platform that could be applied to plague diagnostics, should a public health need arise. The Company is monitoring developments following the October 2 death of a laboratory worker at a plague r
- SECAmendment: SEC Form 8-K/A filed by Co-Diagnostics Inc.8-K/A - Co-Diagnostics, Inc. (0001692415) (Filer)
- SECSEC Form 8-K filed by Co-Diagnostics Inc.8-K - Co-Diagnostics, Inc. (0001692415) (Filer)
- PRCo-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American TribeUte Indian Tribe Mosquito Abatement Department to bring PCR-based mosquito surveillance testing in houseSALT LAKE CITY, Oct. 8, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has received an order from the Ute Indian Tribe Mosquito Abatement Department for a full Vector Smart® mosquito surveillance laboratory installation. The order represents the Company's first complete Vector Smart laboratory installation for a Native American tribe and will enable the Tribe to perform PCR testing of mosquito pools in house."We are
- PRCo-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne DiseaseNew Executive Order prioritizes improved detection and calls for federal R&D programs for rapid diagnostics for mosquito- and tick-borne diseasesCompany to participate in October 9 Utah Global Health Leadership roundtable and four regional mosquito control conferences this fallSALT LAKE CITY, Oct. 7, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today highlighted the growing commercial momentum of its Vector Smart® mosquito surveillance business following the September 29, 2026 signing of Executive Order 14433, "Eliminating Disease-Carrying
- PRCo-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay DevelopmentEbola Assay in Development for Decentralized Testing on the Co-Dx PCR PlatformSALT LAKE CITY, Oct. 6, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its upcoming participation at WHX Labs Johannesburg, taking place October 6-8, 2026, at the Gallagher Convention Centre in Johannesburg, South Africa.Attendees are invited to join Co-Dx at Booth # H3.L38, where the Company will showcase the Co-Dx PCR platform and the Co-Dx™ PCR MTB test*.Co-Dx's participation comes amid intensified global attention to the ongoing Ebola outbreak i
- SECCo-Diagnostics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Co-Diagnostics, Inc. (0001692415) (Filer)
- SECCo-Diagnostics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Co-Diagnostics, Inc. (0001692415) (Filer)
- PRCo-Diagnostics to Participate in Global Health Events During UN General Assembly WeekEvents Bring Together Global Health Leaders to Examine Tuberculosis and Preparedness for the Next Respiratory PandemicSALT LAKE CITY, Sept. 23, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that Seth Egan, Chief Commercialization Officer, will represent the Company at two global health events during the 81st Session of the United Nations General Assembly in New York City: UNOPS Hosted Partnerships Reception – September 23, 2026: The Company will attend a recept
- SECSEC Form PRE 14A filed by Co-Diagnostics Inc.PRE 14A - Co-Diagnostics, Inc. (0001692415) (Filer)
- PRCo-Diagnostics to Participate in Global Health Roundtable on Ebola and Outbreak InnovationRoundtable discussion, taking place in New York City, will examine the ongoing Ebola outbreak and technologies needed to strengthen future outbreak response.Co-Dx will join officials from the U.S. Department of State's Bureau of Global Health Security and Diplomacy and leaders from across the global health research and development community.SALT LAKE CITY, Sept. 21, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that Seth Egan, Chief Commercialization Officer, will participate in the Global Health Technologies Coalition (GHTC
- PRCo-Diagnostics to Participate in Joint WHO/Unitaid/UNAIDS Annual Consultation Meeting on September 17-18, 2026SALT LAKE CITY, Sept. 17, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will participate in the upcoming joint WHO/Unitaid/UNAIDS Annual Consultation Meeting. Joseph Featherstone, Executive Vice President of Business Development, will represent Co-Dx at the annual meeting, which will be held at the World Health Organization (WHO) headquarters in Geneva, Switzerland, September 17-18, 2026. The annual consultation, convened by WHO in collaboration with UN
- SECCo-Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Co-Diagnostics, Inc. (0001692415) (Filer)
- PRCo-Diagnostics and ReadyGo Collaborate to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with EbolaBlood-based testing could open new markets for the Co-Dx® PCR platform, including HIV and hepatitis B and CCo-Diagnostics and ReadyGo target decentralized Ebola detection as the first application of their collaborationCombining GoCollect® sample preparation with Co-Dx PCR technology could bring blood-based molecular testing closer to patientsCompany to hold in-person press conference and live webcast today at 10:30 a.m. ET SALT LAKE CITY, Sept. 16, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests and ReadyGo Diagnostics Ltd. ("ReadyGo"), a UK-b
- SECCo-Diagnostics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Co-Diagnostics, Inc. (0001692415) (Filer)
- PRCo-Diagnostics to Hold Press ConferenceMedia, analysts and investors are welcome to attend in person or via live webcast, Sept. 16 at 10:30 a.m. ETSALT LAKE CITY, Sept. 15, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will host a press conference and live webcast Wednesday, Sept. 16, 2026, at 10:30 a.m. Eastern Time. Co-Diagnostics Press Conference and Live Webcast:Date: Wednesday, Sept. 16, 2026Time: 10:30 a.m. ET | 8:30 a.m. MTLocation: W New York – Times Square | 1567 Broadway, New York,
- SECCo-Diagnostics Inc. filed SEC Form 8-K: Other Events8-K - Co-Diagnostics, Inc. (0001692415) (Filer)
- INSIDERNew insider Bohrer Daniel claimed ownership of 3,657 shares (SEC Form 3)3 - Co-Diagnostics, Inc. (0001692415) (Issuer)
- PRCo-Diagnostics Completes New Vector Smart® Laboratory Installations Amid Rising Dengue Activity in FloridaTwo full laboratory installations completed in Florida; installation and customer training underway in IndianaState surveillance has recorded 73 locally acquired dengue cases and identifies 14 dengue-positive mosquito pools in Florida this seasonSALT LAKE CITY, Sept. 10, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the completion of two new Vector Smart® mosquito surveillance laboratory installations in Florida, with installation and customer training underway at an additional laboratory in Indiana. The installations bring
- SECSEC Form DEFA14A filed by Co-Diagnostics Inc.DEFA14A - Co-Diagnostics, Inc. (0001692415) (Filer)
- SECCo-Diagnostics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Co-Diagnostics, Inc. (0001692415) (Filer)
- PRCo-Diagnostics Launches Integrated Cloud and Mobile Infrastructure in IndiaLocalized cloud environment is designed to support ongoing clinical studies and establish the digital foundation for future data commercialization strategies SALT LAKE CITY, Sept. 3, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the launch of its integrated cloud infrastructure in India. The deployment is intended to support the Company's ongoing clinical studies for its point-of-care Mycobacterium tuberculosis (MTB) test while establishing the digital foundation for future deployment of the Co-Dx® PCR platform* throughout t
- SECSEC Form EFFECT filed by Co-Diagnostics Inc.EFFECT - Co-Diagnostics, Inc. (0001692415) (Filer)
- PRCo-Diagnostics Expands Vector Smart® Customer Reach with First International Installation in USAF BaseShipments of laboratory equipment and other mosquito abatement materials to overseas USAF base represent first international expansion of Vector Smart product lineSALT LAKE CITY, Sept. 1, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the first international deployment of its Vector Smart® mosquito surveillance platform, to include shipments of laboratory equipment, consumables, and other mosquito abatement reagents and materials to an overseas United States Air Force ("USAF") base.
CODX FAQ
7 questionsWhat does Co-Diagnostics Inc. do?
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and liquid biopsy test for cancer screening. The company also provides tests that identify genetic traits in plant...Where does CODX stock trade?
Co-Diagnostics Inc. (CODX) is listed on NASDAQ.What sector and industry is CODX in?
Co-Diagnostics Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Co-Diagnostics Inc. go public?
Co-Diagnostics Inc. (CODX) completed its IPO in 2026.What are analysts saying about CODX?
Co-Diagnostics Inc. has had 3 recent analyst actions on file. The most recent action was from Sidoti: Neutral with a $500.00 price target on 2022-08-12. Recent price targets range from $500.00 to $1500.00.What companies are similar to CODX?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare CODX side-by-side with any of them on Quantisnow.How can I track CODX on Quantisnow?
Quantisnow aggregates Co-Diagnostics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CODX to receive live email and push alerts on every new disclosure.